Oropharyngeal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Oropharyngeal cancer is a condition where cancerous cells develop in the tissues of the oropharynx, which constitutes the middle part of the pharynx. This area encompasses the tonsils, the back of the tongue, and the posterior throat walls. The pharynx serves as a passage for both air and food. Oropharyngeal cancers are commonly associated with HPV, and a positive HPV-16 polymerase chain reaction test of a biopsy or fine-needle aspiration is suggestive of oropharyngeal origin. Most oropharyngeal cancers are squamous cell carcinomas, thin, flat cells that line the interior of the oropharynx. Oropharyngeal cancer is relatively rare and typically afflicts individuals aged 50 to 80. The primary risk factors are smoking and excessive alcohol consumption. However, there has been a rise in cases among younger people infected with human papillomavirus (HPV). The signs and symptoms of oropharyngeal cancer can vary depending on the specific location, type, stage of cancer, and the individual genetic makeup of the tumor. These symptoms may include A lump in the neck or throat, Difficulty chewing or swallowing, along with pain, Sore throat, Unexplained ear pain, A persistent sore or ulcer lasting more than two weeks, Difficulty in mouth opening or tongue movement, A persistent white patch on the tongue or the lining of the mouth, Coughing up blood. Risk factors for oropharyngeal cancer can be attributed to environmental, behavioral, or genetic factors and include Tobacco use (cigarettes, pipes, cigars, chewing tobacco), Alcohol consumption, Exposure to human papillomavirus (HPV), including HPV type 16, A prior history of head and neck cancer.

·       The global incidence of oropharyngeal squamous cell carcinoma (OPSCC) is estimated to range from approximately 95,000 to 112,000 new cases each year. Over the last few decades, the incidence of OPSCC has been on the rise due to an increase in cases of human papillomavirus-positive (HPV+) OPSCC.

 

Thelansis’s “Oropharyngeal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Oropharyngeal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Oropharyngeal Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Oropharyngeal Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Oropharyngeal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Oropharyngeal Cancer, Oropharyngeal Cancer market outlook, Oropharyngeal Cancer competitive landscape, Oropharyngeal Cancer market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)